HISTOHEMIJSKA KARAKTERIZACIJA EPITELNIH OVARIJALNIH TUMORA
Sažetak
Cilj: Cilj našeg istraživanja je bilo određivanje prognostičke važnosti izmene sekrecije mucina i ekspresije Ki-67 antigena i IgA u tkivu tumora jajnika.
Metode: Tumorsko tkivo jajnika 42 pacijentkinje je histološki obrađivano i bojeno uz pomoć mucinohistohemijskih i imunocitohemijskih metoda.
Rezultati: Na našem materijalu marker proliferacije ćelija se pokazao kao validan prognostički faktor stepena atipije tumorskih ćelija. Imunoglobulin A je verifikovan u značajnoj meri u epitelu i sekretu kod benignih formi, a znatno manje kod malignih formi ovarijalnih neoplazmi. Histohemijska analiza mucina pokazala je izmenu od neutralih do kiselih kako stepen malignosti tumora raste. Istovremeno u poljima anaplazije mucini nedostaju.
Zaključak: Marker proliferacije Ki-67, IgA i izmena sekrecije mucina su validni prognostički faktori kod ovarijalnih neoplazmi.
Reference
http://www.wcrf.org/cancer_statistics/data_specific_cancers/ovarian_cancer_statistics.php
http://www.ocrf.org/news/2014-ovarian-cancer-statistics
Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN.Pathology and classification of ovarian tumors. Cancer. 2003 May 15;97(10 Suppl):2631-42
Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF.Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4
Deligdisch L, Pénault-Llorca F, Schlosshauer P, Altchek A, Peiretti M, Nezhat F. Stage I ovarian carcinoma: different clinical pathologic patterns. Fertil Steril. 2007 Oct;88(4):906-10.
Wang S, Ma XY, Xia Y, Zhang LH. Expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors. Sichuan Da Xue Xue Bao Yi Xue Ban. 2010 Jul;41(4):575-80
Aune G1, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol. 2011 Jun 20;4(5):444-53
Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009 Dec;9(12):874-85
Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D, Batra SK. Altered Expression of Transmembrane Mucins, MUC1 and MUC4, in Bladder Cancer:Pathological Implications in Diagnosis. PLoS One. 2014 Mar 26;9(3):e9274
Günther C, Neumann H, Vieth M. Esophageal epithelial resistance. Dig Dis. 2014;32(1-2):6-10
N J Mantis , N Rol and B Corthésy. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunology (2011) 4, 603–611
Catros-Quemener V1, Bouet F, Genetet N. Antitumor immunity and cellular cancer therapies. Med Sci (Paris). 2003 Jan;19(1):43-53
Kondi-Paphitis A1, Carvounis H, Kairi E, Frangou M, Papayanopoulou A, Deligeorgi H. Expression of a local immune defense system in the female genital tract. An immunohistochemical study. Eur J Gynaecol Oncol. 1999;20(2):141-3
Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol. 2013 Oct 15;191(8):4121-9
Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med. 2013 Aug;5(8):1213-26
Noya V, Bay S, Festari MF, García EP, Rodriguez E, Chiale C, Ganneau C, Baleux F, Astrada S, Bollati-Fogolín M, Osinaga E, Freire T. Mucin-like peptides from Echinococcus granulosus induce antitumor activity. Int J Oncol. 2013 Sep;43(3):775-84
Gaidzik N, Kaiser A, Kowalczyk D, Westerlind U, Gerlitzki B, Sinn HP, Schmitt E, Kunz H. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues. Angew Chem Int Ed Engl. 2011 Oct 10;50(42):9977-81